Physician profile
Jeri Mendelson
NPI 1134167182
$875.62
in general payments reported to CMS, 2019-2025
13 companies · $60.00 in 2025
The $60.00 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.66 · 2020: $86.74 · 2021: $191 · 2022: $120 · 2023: $194 · 2024: $147 · 2025: $60.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $252.45 | 2022-2025 | Otezla |
| Ucb, INC. | $150.40 | 2021-2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $142.75 | 2021-2023 | Dupixent |
| Abbvie INC. | $92.42 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $67.14 | 2019-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $34.60 | 2022-2023 | Valchlor |
| Genzyme Corporation | $24.31 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.71 | 2019 | |
| Lilly USA, LLC | $20.78 | 2023 | Taltz, Olumiant |
| Janssen Biotech, INC. | $20.36 | 2020 | |
| Incyte Corporation | $16.69 | 2022 | |
| Dermira, INC. | $15.61 | 2020 | |
| Pfizer INC. | $15.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeri Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.